Exelixis reported a strong fiscal year 2025, with US Cabometyx (cabo) franchise net product revenues growing 17% year-over-year to approximately $2.12 billion. Fourth quarter US cabo revenues grew 6% to $547 million, driving total quarterly revenues to $599 million. The company achieved a GAAP net income of $244.5 million ($0.88 diluted) and non-GAAP EPS of $0.94. Key performance drivers included continued market leadership in Renal Cell Carcinoma (RCC) and rapid growth in Neuroendocrine Tumors (NETs), which exceeded $100 million in annual revenue. Strategically, the company is transitioning to a multi-franchise model following the FDA acceptance of the NDA for zanzalintinib (ZANZA) in third-line plus colorectal cancer (CRC), with a PDUFA date set for December 2026. Management expressed high confidence in 2026, citing a robust balance sheet with $1.66 billion in cash, the expansion of the GI sales force, and significant progress in the pipeline with seven ongoing pivotal ZANZA trials.
| Metric | Value | Change |
|---|---|---|
| Total Revenue (Q4 2025) | $599 million | N/A |
| US Cabo Franchise Net Product Revenue (FY 2025) | $2.12 billion | +17% |
| US Cabo Franchise Net Product Revenue (Q4 2025) | $547 million | +6% |
| Global Cabo Franchise Net Product Revenue (FY 2025) | $2.89 billion | N/A |
| GAAP Net Income (FY 2025) | $244.5 million | N/A |
| Non-GAAP EPS (Diluted) | $0.94 | N/A |
| Cash and Marketable Securities | $1.66 billion | N/A |
| Share Repurchases (FY 2025) | $954 million | N/A |
| Gross to Net (Q4 2025) | 28.5% | N/A |
Exelixis is executing a clear 'multi-franchise' strategy to diversify beyond its foundational CABOMETYX asset. Management emphasized a singular focus on building franchises in solid tumor oncology, specifically expanding from Genitourinary (GU) dominance into Gastrointestinal (GI) indications. This is evidenced by the acceptance of the NDA for ZANZA in colorectal cancer and the expansion of the GI sales team in January to prepare for this launch. The strategic intent is to capture a greater share of the commercial opportunity by having multiple entry points in tumor types, thereby mitigating reliance on a single product lifecycle.
The commercial preparation for ZANZA is a critical near-term catalyst. The company has not only filed the NDA based on STELLAR-303 data but is also actively building infrastructure, specifically expanding the GI sales team earlier than usual to drive CABOMETYX growth in NETs and prepare for the ZANZA launch. Management noted that the new representatives are already gaining experience selling CABO, which lowers the risk and ramp time for the ZANZA launch. This 'footprint expansion' signals management's confidence in the market potential of ZANZA despite the competitive CRC landscape.
The pipeline depth for ZANZA is a major strategic asset, with seven ongoing or planned pivotal trials. Management highlighted the rapid advancement of ZANZA in non-clear cell RCC (STELLAR-304) with data expected mid-2026, and the initiation of STELLAR-316 in molecular residual disease (MRD) CRC. The focus on MRD represents a high-value strategic move into earlier disease settings, which could significantly expand the addressable patient population. Furthermore, the active engagement with Merck on combinations (belzutifan) indicates a strategy to establish ZANZA as the TKI partner of choice in immuno-oncology.
Capital allocation remains disciplined, focusing on internal growth and shareholder returns. The company repurchased $954 million of stock in FY2025 and has $590 million remaining authorization, which they committed to completing in 2026. This aggressive buyback program signals management's belief that the stock is undervalued and provides a floor for the stock price. Additionally, business development efforts are focused on 'back-end loaded pay-for-success transactions' in GU and GI spaces, suggesting a prudent approach to M&A that minimizes upfront risk.
Gross-to-net (GTN) pressure is expected to increase significantly in 2026, rising from 28.5% in Q4 2025 to an estimated 31-32% for the full year. Management attributed this to the loss of the small manufacturer exemption (requiring a 2% Medicare Part D discount) and variability in 340B pricing. This headwind will likely compress net revenue growth relative to gross sales, potentially impacting margins and the perceived quality of earnings growth if not carefully managed.
The regulatory path for ZANZA carries some risk regarding the non-liver metastases (NLM) subset of the STELLAR-303 trial. While the trial met its primary endpoint in the intention-to-treat (ITT) population, the data for the NLM subgroup were immature at the cutoff and are not expected until mid-2026, after the PDUFA date in December. Management stated the NLM data showed only a 'trend.' If the final NLM analysis fails to show statistical significance, it could restrict the label or create hesitation among oncologists, limiting the commercial uptake of the drug.
The competitive landscape in Renal Cell Carcinoma (RCC) is intensifying, which threatens the CABOMETYX cash cow. Analysts asked about upcoming data at ASCO GU that could challenge Cabo in the second-line setting. Management was defensive, emphasizing that overall survival (OS) is the metric that changes practice, implying that upcoming competitor data might only show PFS benefits. However, the mere fact that management is actively discussing competitive defenses highlights the risk of market share erosion in the core RCC franchise.
Management provided limited concrete details on 2026 financial guidance during the call, referring analysts to a slide deck instead of stating numbers verbally. While they announced guidance at a prior conference, the lack of verbal repetition on the call creates a slight transparency concern. Furthermore, regarding ZANZA pricing, management deflected questions about market trends, refusing to speculate on launch pricing despite acknowledging industry trends toward higher prices to offset IRA impacts. This leaves investors guessing on the revenue potential per patient for the new franchise.
Overall: Management conveyed a highly confident and enthusiastic demeanor throughout the call, emphasizing execution and momentum. They described 2025 as 'transformational' and 2026 as a potential inflection point with the upcoming ZANZA launch. The tone shifted from celebrating past Cabo successes to a focused, operational readiness for the future, particularly regarding the expansion of the commercial team and the advancement of the ZANZA pipeline.
Confidence: HIGH - Management used definitive language regarding their strategic direction ('singular focus', 'decisive steps') and financial health ('confident we have the balance sheet'). They provided specific timelines for clinical data and commercial preparations, suggesting strong internal visibility and control over execution.
Estimated to be between 31-32%
Detailed on Slide 19 of earnings presentation (announced at JPM)
Commitment to complete remaining $590 million authorization in 2026
Expected around midyear 2026
Expected to initiate around midyear 2026
Hedging & Uncertainty: Management generally used strong, confident language ('transformational', 'accelerate', 'decisive steps'), but employed hedging when discussing specific future data points and competitive dynamics. For example, regarding the STELLAR-303 NLM data, Dana Aftab stated the data 'showed a trend in overall survival favoring the combination' but noted they 'were immature,' using temporal hedging to manage expectations for the mid-year readout. Christopher Senner used probabilistic hedging regarding 340B impact, stating 'we expect variability' rather than giving a specific forecast. CEO Michael Morrissey also hedged on the small manufacturer discount duration, saying 'I think we are okay there for a while' and 'Do not want to speculate on the timing,' indicating uncertainty about the regulatory timeline for that specific financial benefit.
"2025 was a transformational year for Exelixis, with strong growth across all components of our business." - Michael Morrissey, President and CEO
"We are excited to accelerate ZANZA as our next potential oncology franchise opportunity in 2026." - Michael Morrissey, President and CEO
"We are confident we have the balance sheet expected free cash flows advance our pipeline priorities." - Michael Morrissey, President and CEO
"The entire organization is rallying around this important 2026 milestone." - Michael Morrissey, President and CEO
"We are pursuing back-end loaded pay-for-success transactions that fit into our oncology franchise framework as a top priority." - Michael Morrissey, President and CEO
"We estimate that our gross to net for the full year 2026 will be between 31-32%." - Christopher Senner, Chief Financial Officer
"Physicians are responding positively to the broad net label and the contemporary trial design." - Patrick Joseph Haley, Executive Vice President of Commercial
"We believe that the STELLAR-303 results demonstrate clear clinical differentiation of ZANZA from other TKIs." - Dana Aftab, Executive Vice President of Research and Development
Analyst Sentiment: Analysts were generally inquisitive and focused on the sustainability of growth, specifically asking about the drivers of RCC growth, the competitive landscape, and the specifics of the ZANZA launch. There was notable interest in the financial mechanics, such as gross-to-net impacts and the cadence of share repurchases, suggesting investors are looking for validation of the company's capital efficiency.
Management Responses: Management responses were detailed and prepared, often redirecting focus to the 'franchise' strategy and long-term value. When pressed on competitive threats in RCC, management became defensive, emphasizing that overall survival is the metric that changes standards of care, implying that competitor data on progression-free survival might be insufficient. They were transparent about financial headwinds like gross-to-net but remained firm on their strategic confidence.
Discussion on the durability of CABOMETYX growth in RCC and NETs, with management highlighting market share gains and the expansion of the sales force to drive community uptake.
In-depth questioning on the STELLAR-303 NDA and the immature data for the non-liver metastases population, with management clarifying the timeline for the final analysis.
Inquiries regarding the 'small manufacturer' discount and its duration, where management provided a nuanced answer about revenue thresholds.
Questions on the competitive landscape in RCC, specifically regarding upcoming data readouts, and management's stance on the necessity of Overall Survival (OS) data.
Discussion on ZANZA pricing trends and market access, where management acknowledged industry trends but declined to speculate on specific pricing for ZANZA.
Exelixis presents a compelling investment case driven by the successful execution of its core CABOMETYX franchise and the high-probability launch of its second franchise, ZANZA, in 2026. The company has demonstrated consistent double-digit revenue growth and robust free cash flow generation, which supports an aggressive share repurchase program that effectively returns capital to shareholders while funding a deep pipeline. The transition to a multi-franchise oncology company de-risks the stock by reducing reliance on a single asset. The acceptance of the ZANZA NDA with a PDUFA date in December 2026 serves as a near-term catalyst. While gross-to-net headwinds and competitive data in RCC present risks, management's confident tone and strategic expansion into GI indications (NETs and CRC) provide a clear path for sustained long-term growth. The valuation appears supported by the strong balance sheet and the potential for ZANZA to exceed CABO's commercial success.
Management highlighted increasing pressure on gross-to-net (GTN) margins, estimating a rise to 31-32% in 2026 from 28.5% in Q4 2025. This is driven by the loss of the 'small manufacturer' status (incurring a 2% Medicare Part D discount) and variability in 340B pricing. This reflects a broader macro trend of eroding net prices in the pharmaceutical sector due to regulatory changes.
Management acknowledged a recent trend of higher launch prices for cancer therapies, potentially as a mechanism to offset the impacts of the Inflation Reduction Act (IRA). While they did not commit to a specific price for ZANZA, the acknowledgment of this industry trend suggests a favorable pricing environment for new oncology launches, which could support better-than-expected net revenue realization for ZANZA.